soul trial oral semaglutide cardiovascular outcomes 2025 results found to lower risk of heart failure events in people with type 2 diabetes soul trial oral semaglutide cardiovascular

So this is really about how we we offer that end-to-end support, and thats where we see the opportunity. Holland & Barrett is also continuing to invest in its own-brand weight management ranges, with new launches planned throughout 2026 and beyond.

Both are once-weekly injections, but Mounjaro (tirzepatide) activates GIP and GLP-1 receptors, while Ozempic (semaglutide) targets GLP-1 only

[DOI] [PubMed] [Google Scholar] 178.Janssen B., Hohenadel D., Brinkkoetter P., Peters V., Rind N., Fischer C., Rychlik I., Cerna M., Romzova M., de Heer E., et al

That is why it is grouped with other research peptides rather than with approved medicines

Several GLP-1 receptor agonists are available, with varying pharmacokinetic profiles and approved indications

J.ConnorH.WardJ